Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company's segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company's lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient's eye to improve that patient's ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company's solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:LENS
- CUSIP: N/A
- Web: www.presbia.com
- Market Cap: $46.23 million
- Outstanding Shares: 17,122,000
- 50 Day Moving Avg: $2.33
- 200 Day Moving Avg: $2.82
- 52 Week Range: $1.86 - $5.15
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.51
- P/E Growth: 0.0000
- Annual Revenue: $16,000.00
- Price / Sales: 2,603.72
- Book Value: $0.88 per share
- Price / Book: 2.78
- EBIDTA: ($16,180,000.00)
- Return on Equity: -150.75%
- Return on Assets: -124.15%
- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 5.03%
- Quick Ratio: 6.51%
- Average Volume: 22,628 shs.
- Beta: 0.16
- Short Ratio: 0.04
Frequently Asked Questions for Presbia PLC (NASDAQ:LENS)
What is Presbia PLC's stock symbol?
Presbia PLC trades on the NASDAQ under the ticker symbol "LENS."
How were Presbia PLC's earnings last quarter?
Presbia PLC (NASDAQ:LENS) issued its quarterly earnings results on Friday, August, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07. The firm earned $0.01 million during the quarter, compared to analysts' expectations of $0.04 million. View Presbia PLC's Earnings History.
When will Presbia PLC make its next earnings announcement?
Where is Presbia PLC's stock going? Where will Presbia PLC's stock price be in 2017?
3 equities research analysts have issued 1 year price objectives for Presbia PLC's shares. Their predictions range from $12.00 to $12.00. On average, they expect Presbia PLC's stock price to reach $12.00 in the next year. View Analyst Ratings for Presbia PLC.
Who are some of Presbia PLC's key competitors?
Some companies that are related to Presbia PLC include Neovasc (NVCN), Edap Tms S.A. (EDAP), Digirad Corporation (DRAD), Electromed (ELMD), Biolase (BIOL), Luna Innovations Incorporated (LUNA), Invivo Therapeutics Holdings Corp (NVIV), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Dynatronics Corporation (DYNT), Xtant Medical Holdings (XTNT), Dextera Surgical (DXTR), Sphere Medical Holding PLC (SPHR), PhotoMedex (PHMD), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI) and Hansen Medical (HNSN).
Who are Presbia PLC's key executives?
Presbia PLC's management team includes the folowing people:
- Ralph H. Thurman, Executive Chairman of the Board
- Todd Cooper, President, Chief Executive Officer, Director
- Jarett Fenton, Chief Financial Officer, Secretary
- John Strobel, Vice President of Sales
- Gerd Auffarth M.D., Ph.D., Director
- Robert J. Cresci, Director
- Gerald Farrell Ph.D., Director
- Vladimir Feingold, Director
- Zohar Loshitzer, Director
When did Presbia PLC IPO?
(LENS) raised $50 million in an IPO on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO.
Who owns Presbia PLC stock?
Presbia PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.15%) and Vanguard Group Inc. (0.37%). Company insiders that own Presbia PLC stock include Gerald Farrell, Randy H Thurman, Richard Fogarty, Richard S Ressler, Robert J Cresci, Todd Cooper and Zohar Loshitzer. View Institutional Ownership Trends for Presbia PLC.
Who sold Presbia PLC stock? Who is selling Presbia PLC stock?
Who bought Presbia PLC stock? Who is buying Presbia PLC stock?
Presbia PLC's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have bought Presbia PLC stock in the last two years include Gerald Farrell, Randy H Thurman, Richard Fogarty, Richard S Ressler, Robert J Cresci, Todd Cooper and Zohar Loshitzer. View Insider Buying and Selling for Presbia PLC.
How do I buy Presbia PLC stock?
Shares of Presbia PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Presbia PLC's stock price today?
MarketBeat Community Rating for Presbia PLC (NASDAQ LENS)MarketBeat's community ratings are surveys of what our community members think about Presbia PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Presbia PLC stock can currently be purchased for approximately $2.43.
Consensus Ratings for Presbia PLC (NASDAQ:LENS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||3 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$12.00 (393.20% upside)|
Analysts' Ratings History for Presbia PLC (NASDAQ:LENS)
(Data available from 8/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/23/2017||HC Wainwright||Reiterated Rating||Buy||$12.00||Low|
|5/22/2017||Rodman & Renshaw||Lower Price Target||Buy -> Buy||$14.00 -> $12.00||Medium|
|10/4/2016||Jefferies Group LLC||Upgrade||Market Perform -> Market Outperform||N/A|
Earnings History for Presbia PLC (NASDAQ:LENS)Earnings History by Quarter for Presbia PLC (NASDAQ LENS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/18/2017|| || || || || || || || |
|8/12/2016||Q3 2016||($0.25)||($0.32)||$0.04 million||$0.01 million||View||N/A|
|3/25/2016||Q2||($0.26)||($0.29)||$0.04 million||$0.03 million||View||N/A|
|8/6/2015||Q2 2015||($0.29)||($0.40)||$0.40 million||$0.04 million||View||N/A|
Earnings Estimates for Presbia PLC (NASDAQ:LENS)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS
Dividend History for Presbia PLC (NASDAQ:LENS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Presbia PLC (NASDAQ:LENS)
Insider Ownership Percentage: 74.70%Insider Trades by Quarter for Presbia PLC (NASDAQ:LENS)
Institutional Ownership Percentage: 19.58%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/17/2016||Gerald Farrell||Director||Buy||5,000||$4.65||$23,250.00|| |
|12/17/2015||Richard S Ressler||Director||Buy||500||$6.00||$3,000.00|| |
|12/10/2015||Richard S. Ressler||Director||Buy||499||$6.00||$2,994.00|| |
|12/2/2015||Richard S. Ressler||Director||Buy||1,300||$5.86||$7,618.00|| |
|11/25/2015||Randy H Thurman||Chairman||Buy||1,833||$5.45||$9,989.85|| |
|11/24/2015||Richard S Ressler||Director||Buy||2,300||$4.97||$11,431.00|| |
|11/20/2015||Richard Fogarty||CAO||Buy||1,000||$4.00||$4,000.00|| |
|11/19/2015||Robert J. Cresci||Director||Buy||10,000||$3.97||$39,700.00|| |
|11/19/2015||Zohar Loshitzer||Insider||Buy||5,500||$4.00||$22,000.00|| |
|11/18/2015||Todd Cooper||CEO||Buy||7,500||$3.99||$29,925.00|| |
|5/26/2015||Richard Fogarty||CAO||Buy||1,000||$8.60||$8,600.00|| |
|5/20/2015||Randy H Thurman||Chairman||Buy||11,110||$8.96||$99,545.60|| |
|2/3/2015||Richard S Ressler||Director||Buy||500,000||$10.00||$5,000,000.00|| |
Headline Trends for Presbia PLC (NASDAQ:LENS)
Latest Headlines for Presbia PLC (NASDAQ:LENS)
|ETFs with exposure to Presbia Plc : August 1, 2017|
finance.yahoo.com - August 2 at 3:04 AM
|ETFs with exposure to Presbia Plc : July 3, 2017|
finance.yahoo.com - July 3 at 7:51 PM
|ETFs with exposure to Presbia Plc : June 19, 2017|
finance.yahoo.com - June 19 at 5:17 PM
|Comparing Entellus Medical (ENTL) and Presbia PLC (LENS)|
www.americanbankingnews.com - June 17 at 10:44 AM
|ETFs with exposure to Presbia Plc : June 5, 2017|
finance.yahoo.com - June 5 at 6:59 PM
|Presbia Plc :LENS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017|
finance.yahoo.com - June 2 at 7:40 PM
|Presbia to Participate in Jefferies 2017 Global Healthcare Conference|
finance.yahoo.com - May 31 at 5:31 AM
|Presbia PLC (LENS) Earns Buy Rating from HC Wainwright|
www.americanbankingnews.com - May 28 at 7:24 AM
|Presbia PLC (LENS) Cut to Sell at Zacks Investment Research|
www.americanbankingnews.com - May 25 at 12:38 AM
|Rodman & Renshaw Lowers Presbia PLC (LENS) Price Target to $12.00|
www.americanbankingnews.com - May 22 at 8:16 AM
|Presbia to Participate in the 2017 ASCRS Symposium & Congress in Los Angeles, California|
finance.yahoo.com - May 3 at 10:24 PM
|Presbia PLC (LENS) Earning Somewhat Negative News Coverage, Report Shows|
www.americanbankingnews.com - May 3 at 12:14 PM
| Brokerages Expect Presbia PLC (LENS) Will Announce Earnings of -$0.15 Per Share|
www.americanbankingnews.com - May 3 at 12:04 AM
|Presbia PLC (LENS) Given Daily Media Sentiment Rating of -0.10|
www.americanbankingnews.com - April 30 at 8:22 AM
|Presbia PLC (LENS) Receiving Somewhat Negative Press Coverage, Report Finds|
www.americanbankingnews.com - April 25 at 1:24 PM
|Presbia PLC (LENS) Getting Somewhat Negative Media Coverage, Report Finds|
www.americanbankingnews.com - April 17 at 9:13 AM
|Zacks: Brokerages Anticipate Presbia PLC (LENS) Will Post Earnings of -$0.15 Per Share|
www.americanbankingnews.com - April 11 at 6:04 PM
|Short Interest in Presbia PLC (LENS) Decreases By 32.5%|
www.americanbankingnews.com - April 10 at 4:16 PM
|Zacks: Brokerages Set $12.50 Target Price for Presbia PLC (LENS)|
www.americanbankingnews.com - April 4 at 12:01 AM
|6:15 pm Presbia extends shareholder rights offering for up to 4.5 mln ordinary shares to March 8 from February 23|
us.rd.yahoo.com - February 23 at 11:16 PM
|PRESBIA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
us.rd.yahoo.com - February 22 at 6:24 PM
|Presbia Announces Extension of Rights Offering|
uk.finance.yahoo.com - February 22 at 6:24 PM
|Form 424B4 Presbia PLC|
www.streetinsider.com - January 27 at 8:27 PM
|Presbia Announces Price and Key Dates Related to Rights Offering|
uk.finance.yahoo.com - January 26 at 8:01 PM
|5:00 pm Presbia announces the key dates relative to its rights offering|
finance.yahoo.com - January 26 at 8:01 PM
|Presbia PLC (LENS) Looks Good: Stock Adds 8.2% in Session|
finance.yahoo.com - December 6 at 10:15 AM
|Presbia to Participate in the 2016 Aegis Capital Growth Conference|
finance.yahoo.com - September 20 at 11:01 AM
|Presbia to Participate in the Rodman & Renshaw 18th Annual Healthcare Conference|
finance.yahoo.com - September 7 at 9:25 AM
|Presbia to Participate in the 2016 Baird Global Health Conference|
finance.yahoo.com - September 1 at 8:58 AM
|Presbia (LENS) Unit Completes Acquisition of Neoptics AG|
www.streetinsider.com - August 22 at 10:31 AM
|PRESBIA PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - August 10 at 8:54 AM
|PRESBIA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition|
biz.yahoo.com - August 8 at 6:09 PM
|Combined Cataract and Presbia Microlens Surgeries Demonstrate Excellent Results and Patient Satisfaction in Near-Vision Improvement|
finance.yahoo.com - July 18 at 8:00 AM
|Presbia to Participate in the 2016 Australasian Society of Cataract and Refractive Surgeons 20 th Annual Conference|
www.businesswire.com - July 12 at 10:20 AM
|Top U.S. LASIK Surgeon Supports Presbia’s Microlens as Solution to Near-Vision|
finance.yahoo.com - June 2 at 8:00 AM
|Here's Why Presbia Is Worth $14/Share, Despite Plummeting Monday|
feeds.benzinga.com - May 23 at 1:49 PM
|Rodman & Renshaw Initiates 'Unsung' Presbia With Buy; Stock Jumps|
feeds.benzinga.com - May 10 at 2:56 PM
|Coverage initiated on Presbia by Rodman & Renshaw|
finance.yahoo.com - May 10 at 7:07 AM
|PRESBIA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits|
biz.yahoo.com - May 2 at 5:05 PM
|PRESBIA PLC Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 28 at 6:03 AM
|First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits|
finance.yahoo.com - March 1 at 8:00 AM
Presbia PLC (LENS) Chart for Thursday, August, 17, 2017